VA-REGULA-FORENSICS
14.9.2023 09:01:34 CEST | Business Wire | Press release
The identity verification industry has evolved significantly in recent years, expanding its scope beyond traditional Know Your Customer (KYC) processes. As IDV is becoming the new norm, more identity verification providers are vying for the attention of potential customers.
While the market is becoming a buyer’s market, it can also be confusing because of the many seemingly similar offers. As Gartner notes, “It is challenging for end-user organizations to select a vendor in a crowded market. Many tend to simply select vendors with experience and presence in their country or region.” However, it’s more important than ever before to have comprehensive selection criteria when choosing a solution.
The two pillars of identity verification: Document authenticity and liveness check
In the era of digital nomadism, it’s an advantage for a vendor to have global coverage of supported IDs. Not only is it a plus for user experience, but it also provides qualitative attributes for effective fraud prevention.
Also, remote interactions are paramount in most scenarios. A proper solution should offer an extensive set of document verification checks, from automatic document type recognition to NFC-based verification (the most trustworthy method). Concerning the latter, an effective solution should allow re-verification of electronic chips by processing results on a server, thus eliminating the risk of accepting a tampered ID.
As for binding the ID to the actual individual, it may already be not enough to ask users to take selfies (passive liveness check). Organizations need to be able to detect various biometric fraud, including injection attacks, and be able to compare live biometrics with the photo on the document and the data encoded in the chip embedded in the ID.
All in all, it’s crucial for a vendor to deliver a complete verification solution that tackles everything mentioned above. These key tasks are covered by Regula’s products acknowledged in the report—Regula Document Reader SDK and Regula Face SDK. Together, they form a solid future-proof foundation for reliable identity verification.
Beyond the basics
Given the evolving landscape of security challenges and the growing demand for comprehensive solutions, organizations are looking for tools that can offer more than just the basics. Vendors are expected to stand out by adding more value through augmenting core capabilities with novel implementation approaches and the ability to handle AI-enabled attack vectors.
According to Regula’s latest survey, in the past year, 37% of organizations encountered incidents of deepfake voice fraud, while 29% fell victim to deepfake videos. The increasing accessibility of artificial intelligence technology for crafting deepfakes is amplifying these risks, posing a significant challenge for both businesses and individuals.
Regula has taken a proactive approach to fortifying defenses against this threat by investing in a forward-looking roadmap. "When it comes to detecting deepfakes, we believe that neural networks can be valuable for defensive purposes, as long as they come with other anti-fraud measures that focus on physical and dynamic parameters,” says Henry Patishman, VP of Identity Verification Solutions at Regula. “These include face liveness checks, document liveness checks, optically variable security elements, and more. It's still challenging to create deepfakes that show the expected dynamic behavior. Verifying the liveness of an object can provide a crucial advantage against fraudsters. Additionally, cross-referencing user information with biometric checks and recent transaction history can enhance the verification process."
*Gartner, Market Guide for Identity Verification, Akif Khan, 7 September 2023
About Gartner
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Proofing and Affirmation in 2022. Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230915253195/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
